A biopharmaceutical company developing oral pills for hereditary angioedema, a rare genetic disorder that causes sudden, painful swelling attacks. Its lead drug candidate, deucrictibant, aims to offer patients a pill instead of the injections they currently use. The company was founded in 2015 in Leiden, the Netherlands, when chemist Jochen Knolle—inventor of the injectable HAE drug icatibant—teamed up with colleagues to create an oral version of the same idea. The name blends "pharma" with a made-up suffix.
Pharvaris announces annual general meeting of shareholders for June 26, 2026
The agenda includes adoption of 2025 annual accounts, appointment of PwC as auditor for 2026, discharge of directors, and re-appointment of Dr. Margareta Elisabeth Björk as non-executive director.
Show detailsHide details
Pharvaris N.V. will hold its annual general meeting on June 26, 2026 at 16:00 CEST in Amsterdam, the Netherlands.
Shareholders of record as of May 29, 2026 are eligible to attend and vote; attendance notices must be received by June 24, 2026.
The company has never paid dividends and does not anticipate paying any in the foreseeable future.
The board seeks renewal of authorization to acquire up to 10% of issued share capital for 18 months following the meeting.
Pharvaris N.V. closes underwritten public offering of 4,455,863 ordinary shares at $29.68 per share, raising approximately $124 million in net proceeds.
On May 8, 2026, Pharvaris N.V. entered into an underwriting agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC as representatives of the underwriters.
Show detailsHide details
The offering included the full exercise of the underwriters' option to purchase an additional 581,199 ordinary shares, totaling 4,455,863 shares sold.
The public offering price was $29.68 per share, and the offering closed on May 11, 2026.
Net proceeds are expected to be approximately $124 million after underwriting discounts and commissions.
Proceeds will be used primarily for R&D expenses for late-stage clinical programs, U.S. sales and marketing team expansion, commercialization expenses, working capital, and general corporate purposes.
Pharvaris outlines 2026 priorities; NDA filing for deucrictibant on-demand HAE expected 1H2026
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release tablet for HAE prophylaxis, is anticipated in the third quarter of 2026.
Show detailsHide details
Pharvaris plans to file a U.S. NDA for deucrictibant immediate-release capsule for on-demand treatment of HAE attacks in the first half of 2026.
RAPIDe-3, a pivotal Phase 3 study of deucrictibant for on-demand HAE treatment, met its primary endpoint and all secondary efficacy endpoints with statistical significance; median time to symptom relief was 1.28 hours versus placebo (p<0.0001).
Enrollment is ongoing in CREAATE, a pivotal Phase 3 study of deucrictibant for prophylactic and on-demand treatment of AAE-C1INH attacks.
Pharvaris estimates its cash runway into the first half of 2027.
Pharvaris was added to the Nasdaq Biotechnology Index in December 2025.